Navigation Links
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
Date:8/5/2009

ducts with strong intellectual property and exciting growth prospects. We continue to increase the global reach of our business, and now have a presence in 26 countries worldwide compared to nine countries four years ago.

We have also developed a promising pipeline with encouraging recent news. With the receipt of a Complete Response Letter from the US Food and Drug Administration ("FDA") for INTUNIV, we are confident that we will quickly come to agreement on the final wording of the product label and will launch in the fourth quarter of 2009 as planned. We are also initiating Phase 2 pilot clinical trials to assess the efficacy and safety of VYVANSE in non ADHD ("Attention Deficit Hyperactivity Disorder") indications. Our HGT pipeline has been strengthened by positive results from our trial of velaglucerase in naïve Gaucher patients. A treatment protocol for early access has been approved by the FDA and the agency has approved Fast Track designation for the product. Rolling review of the New Drug Application ("NDA") has started.

Our core portfolio has made good progress in the quarter. We are pleased with the performance of VYVANSE as it has retained market share during the historically quieter summer vacation season in contrast to other branded ADHD treatments that have lost market share. We are anticipating the benefits of the back to school season for VYVANSE and are looking forward to increased sales momentum from our co-promote agreement with GSK for adult ADHD. We are also expecting further positive newsflow from our pipeline during the second half of this year.

Supported by pro-active cost management, our business is well placed to deliver on our unchanged guidance framework for 2009 and looking ahead we reiterate our aspiration of growing sales in the mid-teens range on average between 2009 and 2015."

    Second Quarter 2009 Unaudited Results

                                  
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
2. The Crohns & Colitis Foundation of America and Shire Launch Virtual IBD March on the Hill to Increase Funding for Digestive Disease Research
3. Shire begins the year with a strong performance
4. Shire plc: Results of the Annual General Meeting Held on April 28, 2009
5. Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
6. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
7. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
8. Publication of Shire plcs Annual Report 2008
9. Shires Project Playground Gives Boost to Philadelphia
10. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
11. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global Human Albumin Industry Report 2014" report to ... Industry Report 2014 is a professional and in-depth study ... industry. The report provides a basic overview ... chain structure. The human albumin market analysis is provided ...
(Date:9/18/2014)... 18, 2014 Leatherwood Plastics has ... material, to stay competitive in the semiconductor, clean ... materials ultimately impact product quality and productivity, according ... , Established in 1980 in Lewisville, TX, ... fabricators have left the business. Much of Leatherwood’s ...
(Date:9/18/2014)... 18, 2014  MEI Pharma, Inc. (Nasdaq: MEIP ... novel therapies for cancer, announced today that Daniel P. ... at BioCentury,s NewsMakers in the Biotech Industry conference ... from the Millennium Broadway Hotel & Conference Center in ... presentation can be accessed at www.meipharma.com . A replay ...
(Date:9/18/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ... but separate underwritten offerings of 10,000,000 shares of its ... $2.00 per share, for expected gross proceeds of $20 ... Preferred Stock at a price to the public of ... million. Each share of Series A Convertible Preferred Stock ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... For low-throughput disruption of a wide range of biological samples , ... , , ... of biological samples, including animal,and human tissues and cells and plant tissue. , ... The TissueRuptor system provides: , ...
... , ... and easy silica-based DNA purification in convenient spin-column and 96-well-plate,formats. Most ... for mechanical disruption and reducing,hands-on time. Optimized protocols for specific sample ... veterinary pathogen research applications. , ...
... Tracy Worzella and Brad Larson , Promega Corporation, Madison, WI, USA ... Application Note 138 ... , , Correlated measurement of ... Monitoring of both luminescence and fluorescence output signals from , one assay ...
Cached Biology Technology:TissueRuptor System 2TissueRuptor System 3DNA purification from pig ears to bird blood using proven DNeasy Technology 2Promegas Multiplexed Cell Viability and Apoptosis Assays performed on the PHERAstar 2Promegas Multiplexed Cell Viability and Apoptosis Assays performed on the PHERAstar 3Promegas Multiplexed Cell Viability and Apoptosis Assays performed on the PHERAstar 4Promegas Multiplexed Cell Viability and Apoptosis Assays performed on the PHERAstar 5
(Date:9/18/2014)... Mass. A novel robotic system that can operate ... being tested as part of a biomedical research partnership ... the aim of determining if the robot, in conjunction ... faster, more accurate, less costly, and less discomforting for ... to deliver prostate cancer therapies with greater precision. , ...
(Date:9/18/2014)... starts a "frequent flyers" program, fruit flies surely would ... has hosted increasing numbers of fruit fly research studies. ... in April, and another is scheduled launch to the ... launch in December. , Fruit flies are biomedical research ... space. Model organisms can reveal the basis for health ...
(Date:9/18/2014)... foliage season that prompts millions of Americans to undertake jaunts ... possibly last a little longer within a century, according to ... in some areas of the United States as summer temperatures ... the journal Global Ecology and Biogeography . For instance, ... the state tree of New Hampshire could change color ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4
... ROCKVILLE, MD, USA/BEIJING, CHINA -- The global fight against ... and the China National Biotec Group (CNBG) announce that ... tuberculosis (TB) vaccines. The agreement between the leading non-profit ... corporation in China signals a commitment by both to ...
... Barbara, Calif.) When UC Santa Barbara geochemist David Valentine ... bacteria blooms had consumed almost all of the deepwater methane ... people were skeptical. How, they asked, could almost all of ... disappear? In a new study published in the ...
... location and the political instability in the region have kept ... , But Hyongki Lee, a University of Houston civil engineering ... this mysterious region _ studying it from space. , Lee ... He plans to use unanalyzed satellite images to survey the ...
Cached Biology News:Aeras and CNBG sign agreement on tuberculosis vaccine R&D 2UCSB scientists say topography played key role in Deepwater Horizon disaster 2UCSB scientists say topography played key role in Deepwater Horizon disaster 3UCSB scientists say topography played key role in Deepwater Horizon disaster 4University of Houston wins NASA grant to study Congo River Basin 2
Mouse anti-hepatitis delta virus Class: Antibody Product Group: Bacterial and Viral Antigen...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
Biology Products: